Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
13 hedge funds and large institutions have $30.6M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
272% more capital inflows, than outflows
Capital inflows: $10.7M | Capital outflows: $2.86M
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
8% more funds holding
Funds holding: 12 → 13 (+1)
4.9% more ownership
Funds ownership: 15.5% → 20.4% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$6.47M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.09M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$645K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$252K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$211K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$60.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.68K |
AYLA Hedge Fund Activity: Q3 2021 in Review
13 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q3 2021, worth a combined $30.6M — up 46% from $20.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AYLA positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $6.47M. The largest seller was Sio Capital Management, cutting an estimated $2.69M.
- 13 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q3 2021, up from 12 in Q2 2021.
- Funds reported $30.6M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q3 2021, up 46% quarter-over-quarter.
- 2 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 1 closed out, a net change of +1 holder.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Ikarian Capital, an estimated $6.47M added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Sio Capital Management, an estimated $2.69M sold.
Based on aggregated 13F filings for Q3 2021.